Liraglutide reduces systolic blood pressure in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials

0

Di Zhao 1, Hui Liu 2, Pingshuan Dong 3

Main idea: This data suggest the beneficial effects of liraglutide on cardiovascular protection and may improve prognosis in these patients.

Abstract

The antidiabetic effect of liraglutide in patients with type 2 diabetes mellitus has been explored in several trials. We performed this meta-analysis determining the effects of liraglutide on blood pressure in these patients. Three electronic databases (Pubmed, Web of Science, and Cochrane Central) were searched for all published articles evaluating the effects of liraglutide on blood pressure in subjects with type 2 diabetes mellitus. Total 968 patients were included in 10 randomized, double-blind, placebo-controlled trials with a follow-up of 16 ± 9 weeks. Liraglutide 1.8 mg/day reduced systolic blood pressure (5.39 mm Hg) and body weight (2.07 kg) in patients with type 2 diabetes mellitus. There was no significant difference for changes of diastolic blood. pressure between liragLutide and placebo in these patients. The increases of heart rate were greater than placebo in patients treated with the drug. No correlation was found between reduction of blood pressure and loss of weight in patients who took the drug (p = .24) We conclude that the antidiabetic effect of liragsulide on blood pressure in diabetes patients has been explored in several trials and was not found to be significant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here